CorMedix Inc.
CRMDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Valued at $660.6M, CRMD is a small-cap name in its sector. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Market Cap
$660.6M
Beta
1.48
P/E (TTM)
3.83
P/E (Fwd)
24.06
EPS (TTM)
$2.20
EPS (Fwd)
$0.35
ROE
65.6%
ROA
26.4%
Cash
$178.1M
Total Debt
$147.4M
Free CF
$119.8M
52W Change
-22.5%
Annual Financials
Cash vs Debt
CorMedix Inc. holds $178.1M in cash against $147.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $119.8M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 65.6%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 26.4% further supports the picture of efficient asset utilization. Revenue has been uneven over recent years, ranging from $191K to $311.7M.
As with any equity investment, CRMD carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence CorMedix Inc.'s trajectory.